# A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

> **NCT04702568** · PHASE2 · TERMINATED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 19 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria
- PNH

## Interventions

- **DRUG:** BCX9930
- **DRUG:** Eculizumab
- **DRUG:** Ravulizumab

## Key facts

- **NCT ID:** NCT04702568
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-18
- **Primary completion:** 2023-10-04
- **Final completion:** 2023-10-04
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04702568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04702568, "A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04702568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*